CRISPR-Cas-mediated Multianalyte Synthetic Urine Biomarker Test for Portable DiagnosticsAudrey E. Van Heest 1, Feiyang Deng 1, Renee T. Zhao 2, Nour Saida Harzallah 2,3, Heather E. Fleming 3,4, Sangeeta N. Bhatia 2,3,4,5,6,7,8, Liangliang Hao 1,2,3
1Department of Biomedical Engineering, Boston University, 2Institute for Medical Engineering and Science, Massachusetts Institute of Technology, 3Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 4Howard Hughes Medical Institute, 5Broad Institute of Massachusetts Institute of Technology and Harvard, 6Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, 7Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, 8Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School
This protocol describes a CRISPR-Cas-mediated, multianalyte synthetic urine biomarker test that enables point-of-care cancer diagnostics through the ex vivo analysis of tumor-associated protease activities.
